- United States
- /
- Life Sciences
- /
- NasdaqGS:TEM
Tempus AI (TEM): Evaluating Valuation After FDA Clearance Fuels Optimism in Precision Oncology

Reviewed by Kshitija Bhandaru
Tempus AI’s FDA 510(k) clearance for its RNA-based xR IVD device is a key endorsement that positions the company at the forefront of precision oncology and unlocks fresh opportunities in drug development and data-driven healthcare.
See our latest analysis for Tempus AI.
Tempus AI has enjoyed a recent wave of investor optimism, thanks in part to the FDA’s approval of its xR IVD device and headline initiatives like Ambry CARE’s risk-scoring enhancements. These developments come as the broader sector gains attention from pro-AI policy moves. While the 1-year total shareholder return stands at just 0.73%, momentum appears to be building around the company’s growth outlook in precision diagnostics and data-driven oncology solutions.
If the recent buzz in precision medicine has you searching for more opportunities, consider exploring See the full list for free.
Given surging optimism and Tempus AI’s recent rally, the big question for investors is whether shares are still trading at a reasonable valuation or if future growth is already fully reflected in the price.
Most Popular Narrative: 22.5% Overvalued
Tempus AI’s widely followed narrative suggests that the recent rally has pushed shares significantly above the projected fair value. With a last close of $91.66, this view sees limited upside from current levels and puts valuation front and center.
Significant volume growth and market share gains in both oncology and hereditary/genetic testing indicate that Tempus AI is leveraging its expanding data repository and technological differentiation to outperform competitors, positioning the company for durable top-line revenue growth.
Wondering what fuels this bold outlook? The story hinges on ambitious growth targets, margin transformation, and a future profit multiple that could rival some of the market's hottest sectors. Find out which aggressive projections set this valuation apart and see why analysts are split on what comes next.
Result: Fair Value of $74.82 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, rising competition in AI-driven diagnostics and uncertainty around reimbursement could quickly challenge Tempus AI’s ambitious growth story and valuation.
Find out about the key risks to this Tempus AI narrative.
Build Your Own Tempus AI Narrative
If you see the story differently or prefer your own deep dive, you can uncover insights and build your personalized view in just a few minutes with Do it your way.
A great starting point for your Tempus AI research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
Looking for more investment ideas?
Missing out on smarter opportunities is easy if you stop here. Use Simply Wall Street’s screeners to get ahead and find stocks with real upside now:
- Uncover opportunities in digital assets and global financial innovation by checking out these 78 cryptocurrency and blockchain stocks, which stand at the forefront of blockchain technology.
- Chase high-yield potential for your portfolio and tap into income streams with these 19 dividend stocks with yields > 3%, offering strong payouts above 3%.
- Capitalize on rapid advances in medical intelligence when you consider these 32 healthcare AI stocks, transforming how we treat and diagnose illness.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Tempus AI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:TEM
Limited growth with imperfect balance sheet.
Similar Companies
Market Insights
Community Narratives


